BMY · NYSE
BMY · NYSE
62.68 USD
+1.29 (+2.10%)
BMY rose about 2% pre-market after Bristol Myers reported third-quarter revenue and adjusted earnings above expectations and raised its 2026 revenue outlook. source The company also said it plans to restart paused multiple-sclerosis cell-therapy trials early next year after attributing the prior side effects away from the treatment. source The gain tracked a broader rally in large-cap pharma peers.
BMY rose about 2% pre-market after Bristol Myers reported third-quarter revenue and adjusted earnings above expectations and raised its 2026 revenue outlook. source The company also said it plans to restart paused multiple-sclerosis cell-therapy trials early next year after attributing the prior side effects away from the treatment. source The gain tracked a broader rally in large-cap pharma peers.